ClinicalTrials.gg
CompletedNCT06868589RELIEF-LTUpdated Aug 11, 2026

Reducing Pain With Methadone and Ketamine in Liver Transplant

A Phase 4 interventional study of Methadone and ketamine in Liver Transplantation, sponsored by Lahey Clinic. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Lahey Clinic · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies testing methadone in Pain, Postoperative — 8 open to participants now, 8 under way, 3 of them phase 3. Methadone · Pain, Postoperative.

Enrollment
26th of 37
50 · median 75
Started
2025
with 1 other
Phase 4
21 of 37
4 open now
Registered
31st of 37
by date

Among the 37 studies testing methadone in Pain, Postoperative, this one is the 26th largest by enrollment, is one of 2 that started in 2025, is one of 21 in phase 4, and was the 31st registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

8 of the 37 studies testing methadone in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methadone

Methadone: first FDA approval 1947 (DOLOPHINE HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing methadone in Pain, Postoperative, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if using methadone and ketamine during an adult deceased donor liver transplant can help decrease pain after surgery.

The main questions it aims to answer are:

  • What impact does using methadone and ketamine during a deceased donor liver transplant have on pain after surgery?
  • Does the use of methadone and ketamine also have an impact on mental confusion (delirium) after surgery?

Researchers will compare the use of methadone and ketamine to standard of care to see if the two drugs work to decrease pain and impact delirium after liver transplant.

Participants will:

  • Receive either methadone and ketamine or standard of care during their deceased donor liver transplant.
  • Allow researchers to follow medical care throughout inpatient stay.
Read the detailed description

Pain control following liver transplantation (LT) has been the subject of interest of many research projects due to invasive nature of the procedure, significant comorbidities of recipients, effect of hepatic metabolism on many common pain medications and difficulties in performing some neuraxial and regional techniques given patient coagulopathy. Some newer regional nerve blocks such as External Oblique Intercostal (EOI) block has also been successfully utilized in pain management of patients undergoing liver resections but their utilization in perioperative setting for high-MELD patients and after-hour operations are limited. Methadone and ketamine are well-known drugs that have been recently emerged as components of new pain management pathways in many open surgeries due to their availability, cost, well-known metabolism, good safety profile and prolonged effects. Evidence has emerged that their use is associated with decreased likelihood of development of chronic pain and need for long term opioids. The combination of methadone and ketamine has been shown to be superior to opioids alone due to synergistic effect on N-methyl-d-aspartate and μ-opioid receptors. But these medications have not been extensively studied in LT recipients except for a few case reports and small studies. Current standards of care for intraoperative pain management during LT are systemic short and medium long-acting opioids such as fentanyl and hydromorphone which both have numerous concerns such as respiratory depression and opioid dependency. The aim of this study is to prospectively evaluate the effect of intraoperative methadone and ketamine administration on postoperative pain in liver transplant recipients. These drugs have been safely used during liver transplantation at LHMC and other centers and showed to be effective and safe, but the exact dosing and timing of administration requires further studies.

03

Conditions studied

  • Liver Transplantation

Keywords

  • Liver Transplantation
  • Deceased Donor Liver Transplant
  • Postoperative Pain
  • Methadone
  • Ketamine
  • Perioperative Analgesia
  • Anesthesiology
  • Acute Pain
  • Transplant Surgery
  • Opioids
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients ≥ 18 years of age at the time of LT.
  • Undergoing LT from a deceased donor.
  • Written obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

Exclusion criteria

Exclusion criteria:

  • Living donor liver transplantation (LDLT).
  • Split liver transplantation (isolated right or left lobe).
  • Acute liver failure (ALF) as the indication for LT.
  • Repeat (redo) liver transplant
  • Simultaneous liver and kidney transplant (SLK)
  • Sedation or high vasopressor use.
  • Subject is intubated and/or mechanically ventilated prior to entering the operating room for LT.
  • Severe Hepatic encephalopathy
  • History of psychiatric disorders such as schizophrenia or bipolar mood disorders
  • History of chronic opioid use, substance abuse or opioid maintenance therapies
  • Any history of allergic reaction to any of the study drugs History of Brugadda, prolonged syndrome or QTc in preoperative setting
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
  • Prisoner
  • Pregnant person
  • Operational Exclusion Criterion: Subjects will not be enrolled if study personnel required for protocol execution (e.g., study investigator, research staff or pharmacy staff) are unavailable at the time of transplantation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    M+K group

    Participants in this arm will receive the intervention with methadone and ketamine

    Drug: Methadone · Drug: ketamine

  • Active comparator
    SOC group

    Participants in this arm will receive the standard of care with combination of hydromorphone and fentanyl

    Drug: Hydromorphone · Drug: fentanyl

Interventions

  • Participants in this group will receive one bolus dose of intravenous Methadone and Ketamine at the start of operation

  • Participants in this group will receive one bolus dose of intravenous Methadone and Ketamine at the start of operation

  • Participants in this group will receive standard of care for pain with either intravenous fentanyl and/or hydromorphone boluses during the procedure

  • Participants in this group will receive standard of care for pain with either intravenous fentanyl and/or hydromorphone boluses during the procedure

06

What researchers measure

Primary outcomes

  1. Postoperative Pain

    postoperative opioid consumption (measured as morphine milligram equivalents ((MME)) 48 hours after surgery

    Time frame: 8, 16, 24, 32, 40 and 48hours post-surgery finish

  2. Postoperative Pain

    Subjective postoperative pain scores measured as 0-10 (10 being the worst pain)

    Time frame: 8, 16, 24, 32, 40 and 48hours post-surgery finish

Secondary outcomes

  1. Length of stay in intensive care unit

    Duration of length of stay in intensive care unit in hours

    Time frame: Post surgery finish until discharge from intensive care unit, or date of death from any cause, whichever came first, assessed up to 30 days

  2. Length of stay in hospital

    Duration of length of stay in the hospital in days

    Time frame: Post surgery finish until discharge from hospital, or date of death from any cause, whichever came first, assessed up to 30 days

  3. Delirium

    Incidence of postoperative delirium measured by standard CAM-ICU scores, ICD-10 diagnosis of delirium, any use of anti-agitation medication such as haloperidol, dexmedetomidine or seroquel

    Time frame: Post surgery finish until discharge from intensive care unit, or date of death from any cause, whichever came first, assessed up to 30 days

  4. Respiratory complications

    Any significant respiratory complications such as re-intubation, need for invasive ventilation such as BIPAP or CPAP

    Time frame: Post surgery finish until discharge from intensive care unit, or date of death from any cause, whichever came first, assessed up to 30 days

  5. Narcotics reversal agent

    Any need for narcotics reversal agents such as Naloxone after administration of study drugs

    Time frame: Post surgery finish until discharge from intensive care unit, or date of death from any cause, whichever came first, assessed up to 30 days

  6. Postoperative adjunct pain modalities

    Incidence of usage of any additional pain modalities such as nerve blocks, neuraxial anesthesia, non-narcotic pain medications such as additional ketamine dose, ketorolac, methocarbamol, ketorolac, etc

    Time frame: Post surgery finish until discharge from intensive care unit, or date of death from any cause, whichever came first, assessed up to 30 days

  7. Correlation Between Study Drug Exposure and Early Post-Transplant Laboratory Markers of Liver Dysfunction

    Unit of measure: Correlation coefficient (r) describing the association between study drug exposure and postoperative laboratory markers of liver dysfunction during the first 24hrs post surgery. Independent variables (study drug exposure): * Randomized study drug assignment (e.g., ketamine vs methadone vs standard of care) * Total intraoperative dose of each study drug (total mg) Dependent variables (markers of postoperative liver dysfunction): Correlation coefficients will be calculated between study drug exposure and the following laboratory values measured during first postoperative days : * Peak alanine aminotransferase (ALT), IU/L * Peak aspartate aminotransferase (AST), IU/L * Peak total bilirubin, mg/dL * Peak international normalized ratio (INR)

    Time frame: Immediate to 24hrs post surgery finish

  8. Correlation Between Donor and Surgical Factors and Postoperative Opioid Use (MME)

    Unit of measure: Correlation coefficient (r) describing the association between each donor/surgical factor and total postoperative opioid consumption (MME) during postoperative days 0-2. Total MME will be calculated by converting all administered opioids into morphine milligram equivalents using standard conversion factors. Factors assessed (independent variables): * Donor age (years) * Donation type (donation after brain death vs donation after circulatory death) * Use of normothermic machine perfusion (yes/no) * Cold ischemia time (hours) * Warm ischemia time (minutes) * Surgical technique characteristics (e.g., piggyback vs caval replacement approach, vascular anastomosis techniques, use of veno-venous bypass), coded as categorical variables

    Time frame: From the end of surgery through 48hr post surgery

07

Study locations

2 sites
  • Lahey Clinicc
    Burlington, Massachusetts 01805, United States
  • Lahey Clinic
    Burlington, Massachusetts 01805, United States
08

References and documents

Individual participant data

Plan to share: No — Sensitive transplant data will not be shared for patients privacy

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Mar 2026, 8 months.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 8 months is below that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2025
First posted
Mar 11, 2025
StartActual
Jun 30, 2025
Primary completionActual
Mar 1, 2026
CompletionActual
Jun 1, 2026
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06868589
Lead sponsor
Lahey Clinic
Responsible party
Ryan Nazemian (Staff Anesthesiologist: Division of Transplant, Director: Transplant Anesthesia Fellowship, Co-Director: Anesthesia Informatics, Lahey Clinic) — Principal investigator
First posted
Mar 11, 2025
Start date
Jun 30, 2025
Primary completion
Mar 1, 2026
Completion
Jun 1, 2026
Last update
Aug 11, 2026

Study contacts

Ryan Nazemian, MD, PhD
principal investigator · Lahey Clinic, Department of Anesthesiology, Perioperative and Pain Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methadone · Ketamine

Start the discussion